Synthace Expert Interviews: Cell and Gene Therapies with Dr Damian Marshall

Damian Marshall is the director of new and enabling technologies at the Cell and Gene Therapy Catapult and has almost 20 years of industrial experience gained working for SME’s and large companies. He is responsible for providing vision, expertise and leadership to a team of ~60 scientists working with a wide range of cell and gene therapy developers. Together they are addressing some of the fundamental challenges in the field, developing novel cell and gene therapy manufacturing processes and implementing technologies for advanced product characterisation.

Read More
Synthace Appoints Bob Wiederhold as Chairman of its Board of Directors

Synthace Ltd., the company behind the leading software platform for automating and improving the success rate of biological research, has appointed Silicon Valley veteran Bob Wiederhold as Chairman of its board of Directors. Synthace operates at the intersection of biology and information technology (IT), and Wiederhold brings deep expertise and experience to the company as a result of building multiple successful IT start ups over the last 30 years.

Read More
NewsThe Synthace Team
The failed promise of lab automation

There are a lot of repetitive liquid handling actions in modern biology and to make progress we are expected to pipette carefully, rapidly and with provenance (e.g. record where we pipette to). Occasionally, the cycle breaks, you make an error, I know I have. This means you have to skip a row, start again, mark the data as lost, lose time, stay late etc. My frustration is palpable.

Read More
Synthace collaborates with Oxford BioMedica, Cell and Gene Therapy Catapult and Stratophase

Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, has announced it has agreed, as lead partner, to enter into a collaboration agreement with a consortium of partners, including the Cell and Gene Therapy Catapult, Stratophase Ltd and Synthace Ltd. The agreement is a two-year £2 million collaboration project focused on gene and cell therapy manufacturing, co-funded by the UK’s innovation agency, Innovate UK.

Read More
NewsThe Synthace Team
Cambridge Consultants and Synthace launch new partnership

Product design and development firm Cambridge Consultants is joining forces with innovative software company Synthace in an ambitious bid to unlock the full potential of biology to address many of the global challenges facing the world. The partnership is aimed at boosting adoption of a powerful new platform for the engineering of biological systems – a crucial step towards groundbreaking developments such as truly personalised ‘precision’ medicine and the next generation of antibiotics.

Read More
NewsThe Synthace Team